Skip to main content

Advertisement

Log in

Clinical Oncology/Epidemiology

Serum thyroglobulin as a preclinical tumour marker in subgroups of thyroid cancer

  • Clinical Oncology/Epidemiology
  • Published:
British Journal of Cancer Submit manuscript

Abstract

Serum samples from a biological serum bank taken several years before the diagnosis of cancer, were analysed for S-Tg and S-TSH in 43 patients with thyroid cancer and compared to 128 healthy controls matched for age, sex, geographical region and time of blood sampling. The main finding was the difference in S-Tg between cases and controls, the highest values being found in sera from cases. Relative risk of thyroid cancer increases with increasing S-Tg levels (the global test giving P less than 0.0005). Extremely high levels were found in 4 cases with follicular and 3 with anaplastic cancers. No such statistically significant difference was found in S-TSH concentration. Possible explanations for the elevated S-Tg observed several years before clinically evident malignant tumour are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thoresen, S., Myking, O., Glattre, E. et al. Serum thyroglobulin as a preclinical tumour marker in subgroups of thyroid cancer. Br J Cancer 57, 105–108 (1988). https://doi.org/10.1038/bjc.1988.19

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/bjc.1988.19

  • Springer Nature Limited

Navigation